Gonadorelin
Gonadorelin is a synthetic decapeptide identical to natural GnRH that was FDA-approved decades ago as a diagnostic test of pituitary function (Factrel) and, in a pulsatile-pump form, to treat hypothalamic amenorrhea (Lutrepulse), but both branded products have since been discontinued from the U.S. market, leaving current use mostly confined to off-label fertility and hormone-support protocols.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Gonadorelin is structurally identical to endogenous gonadotropin-releasing hormone (GnRH) and binds the GnRH receptor, a Gq-protein-coupled receptor on pituitary gonadotrope cells. Delivered in short, intermittent pulses that mimic the hypothalamus's natural secretory rhythm, it activates phospholipase C signaling that drives pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Continuous, non-pulsatile exposure instead desensitizes and downregulates the receptor, suppressing gonadotropin output — the opposite pharmacologic effect exploited by long-acting GnRH agonists used for hormone suppression.
Typical results seen in research
In its original diagnostic application, a single dose produces a measurable LH rise that helps clinicians distinguish hypothalamic from pituitary causes of hypogonadism. When given in a pulsatile pattern, it can restore endogenous LH/FSH secretion and downstream gonadal hormone production in people with hypothalamic hypogonadism, and it has been studied as a way to help maintain testicular hormone production and spermatogenesis in men undergoing gonadotropin-suppressing therapies. Its effects depend on an intact, responsive pituitary and are not sustained once administration stops.
How it’s commonly used
Diagnostic testing historically involved a single intravenous or subcutaneous injection with timed blood draws to measure the LH response. Therapeutic pulsatile use required a programmable infusion pump delivering intermittent subcutaneous or intravenous doses, while in current off-label hormone-support contexts it is typically self-administered via subcutaneous injection.
- European Journal of Endocrinology · 2004 Application of gonadotropin releasing hormone in hypogonadotropic hypogonadism--diagnostic and therapeutic aspects
- European Journal of Endocrinology · 1998 Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.